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Introduction 7 
Jha and colleagues introduce the case for increased funding of five health 8 
interventions to control chronic disease in low and middle income 9 
countries: a 33% tax on tobacco; acute management of heart attacks with 10 
low cost drugs; prevention of heart attacks and stroke through salt 11 
reduction by a mix of voluntary manufacturing changes, behaviour 12 
change using mass media and other awareness raising campaigns; 13 
prevention of hepatitis B through immunisation; and secondary 14 
prevention of heart attacks and stroke through a combination of 3–15 
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4 drugs in a ‘generic risk’ pill1. The benefit/cost ratios range, in order, 1 
from 40:1 to 4:1. 2 
The determination of priorities begins with a focus on the current 3 
and expected future burden of disease, as measured by deaths, avoidable 4 
mortality, and cost of illness. The ‘very approximate’ (Jha et al 2012BIB-5 
3_1) discounted benefit-cost ratios are based on comparing a monetised 6 
value of a disability adjusted life year (DALY) with intervention cost. 7 
Evidence on interventions draws largely from the second Disease Control 8 
Priorities Project (DCP 2) (Jamison et al 2006BIB-3_1), Copenhagen 9 
Consensus 2008 paper on disease control (Jamison et al 2008BIB-3_1) and 10 
selected other literature with a reflection that the investments proposed 11 
reflect views of other similar exercises. The five benefit-cost ratios are 12 
subject to sensitivity analyses of single and combined changes in the 13 
following assumptions; changing the discount rate from 3% to 5%, 14 
increasing all costs by 300%, and increasing the value of a DALY from 15 
$1000 to $5000. 16 
The benefit-cost ratios are supplemented, to indicate a move to an 17 
‘idealised’ version, by ‘accounting’ for the value of financial protection 18 
and non-financial costs (e.g. transaction, organisational and 19 
administrative effort to implement the intervention). The ‘accounting’ is a 20 
                                                 
1 E.g. use of aspirin, a statin and an antihypertensive drug (Jamison et al 
2008BIB-3_1) 
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categorisation that relies on: a literature review of various aspects of 1 
health system capacity and; a review of the (limited) evidence on costs 2 
and effects of the Chronic Care Model and its very limited adapted 3 
application to low resource settings. This, at least partly, influences the 4 
qualitative ratings based on the ‘speculative’ judgement of financial 5 
protection and ‘non-financial’ costs by the authors. All interventions are 6 
argued to offer high financial protection with only the impact of 7 
‘capacity’ differentiating the proposed interventions; tobacco taxation is 8 
considered to have low capacity requirements, a salt reduction 9 
programme to have medium capacity requirements and the others to have 10 
high capacity requirements. 11 
The paper ends by calling for an increased role for donor 12 
assistance in controlling chronic diseases despite a concern that this ‘may 13 
not be politically feasible in the short or even medium term’. This role is 14 
also charged to ‘conduct research which makes the marginal costs of 15 
(interventions) affordable’ and includes both more research and 16 
development of relevant health technologies as well as implementation 17 
research to close the gap between knowledge and action. 18 
There is a real challenge in drawing together a justified list of 19 
priorities for funding in an area which is recognised as being both short 20 
of evidence in terms of geographical coverage and range of interventions 21 
evaluated (Suhkre et al 2012BIB-3_1) and hampered by poor quality 22 
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studies (Mulligan et al 2006BIB-3_1). The paper by Jha and colleagues is 1 
therefore a valiant effort to put forward the case for investment in an area 2 
of human life that has a worrying future health and economic impact. 3 
This perspective paper considers whether the best interventions 4 
for investing in the in the improvement of chronic disease are presented 5 
in the challenge paper. It considers: the influence analysis of burden of 6 
illness analysis might have had and should have; the construction and 7 
testing of BENEFIT-COST ratios for the five interventions selected; and 8 
the approach taken to reflecting uncertainty. The paper ends by 9 
suggesting alternative interventions for the expert panel to consider. 10 
Questioning the influence of burden of illness 11 
The paper appears to reflect the premise that the decision problem should 12 
be framed in terms of the burden of disease and, having accounted for the 13 
size of burden, focus on the set of cost-effective interventions to reduce 14 
the burden. Evidence presented points to mental health conditions having 15 
the highest economic burden using the cost-of-illness method and the 16 
second largest using the value of lost output method. However, no 17 
interventions are proposed for addressing this burden. By implication the 18 
authors may have applied a burden of disease approach inconsistently, 19 
adopted a very restricted definition of burden of disease or considered 20 
evidence on benefit-cost ratios for all mental health interventions to be 21 
less than 4:1. These possibilities are considered below. 22 
A 
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It is not clear how estimates of burden in the challenge paper have 1 
been used in practice to narrow down towards the selected interventions. 2 
For example, a burden of illness approach based on mortality rates in 3 
Table 1 would suggest that ischemic and hypertensive heart disease 4 
should be the focus of all interventions. However, this is not the case as 5 
the selected of interventions aim at alleviating heart disease, stroke and 6 
cancer2. Use of avoidable mortality might explain the discrepancy but 7 
these data are not provided by disease and therefore the potential 8 
influence of this approach is unclear. Two further possibilities are that 9 
either the burden of disease approach has been applied inconsistently or it 10 
not been the lens through which cost-effective interventions are selected. 11 
However, if burden of disease is not the original frame it doesn’t explain 12 
why so much information on burden of disease presented without 13 
reference to the impact of health interventions. 14 
Insert table 3.1.1 here 15 
Perhaps interventions to improve mental health are absent because 16 
the impact on mortality is comparatively low. There is a notable absence 17 
of cause of death attributed directly to mental health in Table 1 and a 18 
statement that “we focus chiefly here on changes in mortality ….. simply 19 
because it is far less likely to be misclassified than are the more 20 
                                                 
2 Given an assumption that mortality gains from tobacco tax are split 
equally between cancer and heart disease. 
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subjective measures of disability”. Valuation of health benefits in the 1 
benefit-cost ratio therefore only appear to account for disability averted 2 
when tied to cases of premature mortality. This suggests first that the 3 
burden and impact of chronic disease is massively underestimated as 4 
highly morbid low mortality chronic diseases will be missing from any 5 
estimate of burden presented here. Indeed co-authors of the 6 
challenge paper conclude elsewhere (Bloom et al, 2011BIB-3_1) 7 
that cardiovascular disease and mental health conditions are the 8 
dominant contributors to the global economic burden of non-9 
communicable diseases. Secondly, it implies a further restriction 10 
imposed by the particular burden of disease approach adopted in the 11 
challenge paper – that cost-effective interventions aimed at alleviating 12 
conditions with lower mortality rates are highly unlikely to be 13 
recommended regardless of their cost-effectiveness. For a proposal 14 
focussed on best buys for reducing chronic disease, this seems somewhat 15 
limited and means that the investment proposals presented are unlikely to 16 
reflect the best possible investment possibilities for reducing chronic 17 
disease. 18 
The possibility that the benefit-cost ratios for all mental health 19 
interventions are less than 4:1 is a moot point and the authors provide no 20 
evidence to support or refute this position. However, evidence from 21 
DCP2 (Jamison et al 2006BIB-3_1, p40), on which the challenge paper 22 
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itself draws, supports the case that interventions to reduce mental health 1 
are valid contenders to the proposals offered in the challenge paper. 2 
Evidence from DCP2 (Jamison et al 2006BIB-3_1, p40) indicates 3 
cost-effectiveness ratios for mental health interventions in the area of 4 
alcohol abuse are around $600–800/DALY averted and that treatment for 5 
depression by drugs with episodic or maintenance psychosocial 6 
treatment) is roughly $900–3000/DALY averted. The detailed 7 
DCP2 chapter by Hymen et al (2006)BIB-3_1 suggested that treatment of 8 
depression with episodic treatment using older tricyclic antidepressants 9 
ranged (by World Bank region) between $478–1,288/DALY averted. 10 
More recent evidence suggests that several mental health interventions 11 
could be provided for under $1000/DALY averted in both sub-Saharan 12 
Africa and South East Asia. These include a bundle aimed at alcohol 13 
reduction (including tax increase, reduced access and tax enforcement), 14 
episodic treatment of depression with newer antidepressants (selective 15 
serotonin reuptake inhibitors) and treatment of epilepsy with older anti-16 
epileptics at 80% coverage (Chisholm et al 2012BIB-3_1). 17 
Evidence presented in Jamison et al (2006BIB-3_1, p41) for the 18 
five selected interventions suggests that interventions to improve mental 19 
health compare well. For example, legislation with public education to 20 
reduce salt content was shown to have a cost/DALY averted of around 21 
$2,000 and secondary treatment of AMI and stroke with a polypill to be 22 
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around $700/DALY averted. It is likely therefore, that benefit-cost ratios 1 
of 4:1 or greater for mental health interventions may exist and be on a par 2 
with several of the interventions proposed. This is particularly likely 3 
because the challenge paper converts disability adjusted life years 4 
(DALYs) lost to a monetary value to estimate benefit-cost-ratios without 5 
accounting for other non-money values. 6 
While the absence of interventions for improving mental health 7 
may be of concern, it is only an example and many other cost-effective 8 
interventions could be missing. Of particular concern, given the lack of 9 
clarity in the use of burden of disease estimates in selecting interventions 10 
in this case, is that the proposals could be systematically biased against 11 
recommending the most cost-effective interventions. Why are some 12 
potentially cost-effective treatments of chronic diseases missing? Some 13 
justification of interventions narrowly missing inclusion (e.g. in terms of 14 
benefit-cost ratios or the other criteria) would have helped illuminate the 15 
authors approach more clearly. 16 
Whilst there is unease with the mechanics of using the burden of 17 
illness approach adopted here, of much greater concern is why a burden 18 
is illness approach is used to structure the decision problem. Counting the 19 
size of the epidemiologic or economic problem may indicate problems 20 
for which there are no solutions and could lead to distorted priorities as 21 
more cost-beneficial interventions might never even be considered 22 
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(Williams 1999BIB-3_1, Wiseman and Mooney 1998BIB-3_1). Beginning 1 
with benefit-cost ratios first is more appropriate as it is a solution 2 
focussed approach. It allows a fuller range of potential interventions to be 3 
considered regardless of the focus of disease. It is possible that the most 4 
cost beneficial intervention would also address the disease of highest 5 
burden, but not necessarily. 6 
It is important to recognise that the challenge paper authors were 7 
limited to recommending a maximum of five interventions. In this case it 8 
is not unreasonable to consider burden of disease estimates in order to 9 
benefit from more of the set budget of $75bn. However, to provide the 10 
best buy would require considering benefit-cost ratios before considering 11 
burden of disease. As the methods of combining information on disease 12 
burden and benefit-cost ratios are not clear, it is possible this was done, 13 
but this would be important to see. 14 
Construction and sensitivity of the benefit-cost ratios; 15 
‘Indicative’ benefit-cost ratios are presented in Table 7 of the challenge 16 
paper with details of calculation presented in the text and sensitivity 17 
analysis in the Appendix. Reflecting past research on immunisation for 18 
hepatitis B (Brenzel et al 2006; Sanderson 2005BIB-3_1) I opted to 19 
replicate and reconsider one of the options, using the approach presented 20 
in the paper. Column 2 of Table 1 shows the replication. This indicates a 21 
7:1 ratio which, through the rounding in Table 7 and further recalculation 22 
A 
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to reflect the rounding was increased by the authors to 10:1 (Verguet, 1 
personal communication). The replication therefore satisfactorily reflects 2 
the assumptions of the challenge paper. 3 
The assumptions specific to the hepatitis B vaccination option 4 
were: 5 
<listing> 6 
a. cost per vaccinated child was $3.6, reflecting a study of 7 
India’s national hepatitis B vaccination programme, 8 
b. all benefits would occur 40 years after immunisation; 9 
c. of the 600,000 annual deaths from hepatitis B reported 10 
by WHO, a quarter were considered avoidable by 11 
increasing global vaccination rates from 75% to 100%. 12 
</listing> 13 
While vaccine effectiveness was referred to as 75 and 95%, the increase 14 
from 75–100% coverage appears to implicitly assume 100% 15 
effectiveness, as all 150,000 deaths were considered avertable. All other 16 
assumptions (e.g. value of a DALY averted, discount rate, DALYs lost 17 
per death) were constant across investment options. 18 
In reviewing the benefit-cost calculations three questions arose; 19 
Why were particular data and assumptions adopted?; How valuable were 20 
the sensitivity analyses in exploring these issues?; and, What is the 21 
potential impact of adopting different assumptions? 22 
NL 
NL 
NL 
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Little justification was provided for the hepatitis B vaccination-1 
specific parameter values. As the sensitivity analyses only evaluated 2 
generic assumptions across all options, no sensitivity analysis considered 3 
the impact of option-specific assumptions. Therefore little consideration 4 
was given to the possibility that the benefit-cost ratios might change in 5 
relation to each other. If one (or more) intervention could move 6 
significantly closer to another, differences between options diminish and 7 
this could be of decisional importance. As it is relatively easy to choose 8 
alternative assumptions to effect change in these benefit-cost ratios, the 9 
reasoning for choosing alternative values is important. Therefore this 10 
quick reanalysis reflects sources the authors have cited, and applies 11 
health sector specific evidence to well versed economic arguments (i.e. 12 
rising marginal cost to achieve maximum coverage) to support four 13 
cumulative analyses: 14 
 15 
For achieving more favourable benefit-cost ratios For achieving less favourable 
benefit-cost ratios 
1. Used mean cost from Brenzel et al (2006) 
referenced in challenge paper (range $2.02-$2.37) 
1. Doubled cost of achieving last 
10%-point increase in coverage to 
                                                 
3 Johns and Baltussen (2004)BIB-3_1 showed that marginal costs rose by 
70–100% roughly double for achieving the last 10% coverage of a 
hygiene outreach programme 
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and inflated to the publication year for Indian cost 
data used in base case. New cost was $2.7 per 
vaccinated child. 
achieve 100%3 from $3.6 to $7.2 
per child vaccinated for (the 
effective average cost increased to 
$5.04 from 75–100% coverage) 
2. No amendment made for avoidable mortality as 
assumptions already appeared favourable (future 
burden likely to decline given increasing hep B 
vaccination rates and assumption of 100% efficacy) 
2. Used assumptions on avoidable 
mortality from Brenzel et al (2006) 
3. Used a slightly older coverage rate of 64% 
vaccine coverage from Duclos et al (2009)BIB-3_1. 
While out of date, the% will reflect the position 
for some countries. 
3. Assumed increase of 3% in 
global coverage rates since 2010. 
4. Assumed benefits occurred in 30 rather than 40 
years. 
4. Assumed benefits occurred in 
50 rather than 40 years. 
 1 
Results for the final cumulative step are given in Table 1. The more 2 
favourable assumptions move the benefit-cost ratio from 7:1 to 9:1 and 3 
13:1. The less favourable assumptions move the benefit-cost ratio from 4 
7:1 to 5:1 to 4:1, and finally to 3:1, which is on a par with the generic risk 5 
pill. Further investigation of the impact of alternative option-specific 6 
assumptions for the four other interventions may reveal a credible 7 
alternative positioning of benefit-cost ratios, both in absolute and relative 8 
terms. 9 
Treatment of uncertainty 10 A 
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The challenge paper refers to uncertainty4 in a number of ways: the size 1 
and shape of the future tobacco hazards; greater misclassification of 2 
morbidity compared with mortality statistics; methodological uncertainty 3 
about completeness of data, age weighting and discount rates; 4 
effectiveness of interventions to prevent elevated blood pressure, blood 5 
lipids, and diabetes; and adherence to the polypill. To reflect this, the 6 
benefit-cost estimates are referred to as ‘indicative’ and parameters to 7 
being a ‘ballpark idea’ (e.g. of the economic cost at the macro level). In 8 
each case further information on these issues would reduce uncertainty 9 
and provide more precise estimates. 10 
The challenge paper judges that, given the “often broad ranges in 11 
CE ratios, and hence in benefit-cost ratios, it makes little sense to 12 
conclude with precise estimates or with attempts to quantify statistical 13 
uncertainty around the point estimates”. While there may be little 14 
possibility, given the uncertainties noted, of providing precise estimates, 15 
the conclusion that quantification of uncertainty should therefore be 16 
                                                 
4 This should be distinguished from variation for which further 
information could not increase precision as heterogeneity in patient 
(e.g. age, severity of disease, health outcomes) or health system (e.g. 
price) characteristics refers to real differences. Jha et al mention 
additionally variation in prices, scale of the intervention and 
epidemiological environment. 
Page 577 of 2253 
avoided is a little hasty. Indeed, its avoidance may result in inappropriate 1 
recommendations. 2 
Briggs (1995) showed clearly that knowing the precision of an 3 
incremental cost-effectiveness ratio can affect the decision about which 4 
intervention to implement and indicated that choices may differ from that 5 
implied by point estimates alone. For example, in Figure 1 a decision 6 
maker with a willingness to pay of £10,000 per quality adjusted life year 7 
(QALY) might justifiably prefer intervention C above intervention A or 8 
B, because it is a more precise estimate of the incremental cost-9 
effectiveness ratio even though the point estimate of the cost per QALY 10 
is higher. Since this work, much progress has been made in defining, 11 
measuring and interpreting uncertainty in the context of using economic 12 
evaluation to aid both investment adoption decisions as well as defining 13 
the need for further research. It has also led to much greater emphasis on 14 
the systematic search and review of evidence, as well as methods for 15 
eliciting expert opinion and analysis of evidence that influences the 16 
choice of parameter estimates in economic evaluations of health 17 
interventions (Griffin S and Claxton C 2011). 18 
Insert figure 3.1.1. here 19 
As uncertainty in both costs and effects can vary by intervention 20 
(e.g. Sassi et al, 2009BIB-3_1) it is possible that the benefit-cost ratios 21 
presented in the challenge paper could be differentially affected by 22 
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uncertainty. While it is unusual for uncertainty to be reflected in benefit-1 
cost cost ratios, the analysis of benefit by Jha and colleagues relies 2 
heavily on the value of DALYs averted and is not intrinsically different 3 
from the majority of economic evaluations presented in the health sector. 4 
Therefore analysis of uncertainty could be expected and decisions made 5 
without reference to it could badly mislead understanding of the 6 
likelihood of future costs and benefits. 7 
Evidence to substantiate, refute and counter the priorities 8 
recommended 9 
Two exercises designed to help encourage and guide investment 10 
decisions for controlling chronic disease have recently been published. 11 
The WHO produced three related reports (WHO 2011a, 2011b, 2011c) 12 
outlining the ‘best buys’ for controlling chronic disease and detailed the 13 
costs of scaling up the proposed interventions (to a level where 80% 14 
coverage is achieved within 15 years). A ‘best buy’ was considered to be 15 
an intervention that averts one DALY for less than the average annual 16 
income per capita but is also considered “cheap, feasible and culturally 17 
acceptable to implement”5. 18 
                                                 
5 This contrasts with ‘good buys’ which are other interventions that may 
cost more or generate less health gain but are still considered to 
provide good value for money. 
A 
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As Jha et al state, all five interventions proposed are, at least 1 
partially, reflected in the listing of ‘best buys’. While this is important 2 
corroboration of the value of their investment proposal, there are two 3 
important caveats to accepting this as sufficient validation. First, further 4 
inspection of the ‘best buys’ indicates that several other interventions 5 
could have been selected, but the challenge paper is silent on both their 6 
non-selection and the reasons for their non-selection6. The missing 7 
interventions include entire areas, such as controlling alcohol,7 as well as 8 
competing and complementary interventions for the risk factors 9 
addressed8. Secondly, the reference point for the WHO reports was a 10 
                                                 
6 The need to select is, however, clear as the total cost of the package was 
expected to be $170bn with an average annual cost of $11.4 billion per 
year. 
7 This included restricting access, enforce bans on advertising, raising 
taxes on alcohol, monitoring, advocacy/support. The authors explained 
(personal communication) that, while excess deaths in Russia can be 
linked clearly to binge drinking, the net effect in other populations is 
less clear. However, this decision also appears to be another impact of 
linking morbidity only to cases of mortality. 
8 For diet, these include promoting public awareness about diet and 
physical activity, replacing trans fat with polyunsaturated fat. For 
tobacco it includes smoke-free indoor workplaces and public places, 
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focus on “four diseases; cardiovascular disease, cancer, diabetes and 1 
chronic respiratory disease….(which are) largely caused by four shared 2 
behavioural risk factors; tobacco use, harmful alcohol use, physical 3 
inactivity, and unhealthy diet” (WHO 2011c, p10). Therefore, 4 
confirmation is less convincing as a case for accepting that the best 5 
investments have been presented in the challenge paper, as good 6 
alternatives may exist outside of these disease areas. 7 
A second exercise conducted by WHO focussed on the cost-8 
effectiveness of over 500 single or combined interventions for the 9 
prevention and control of non-communicable diseases and injuries in 10 
countries in sub-Saharan Africa and South East Asia that have high adult 11 
and child mortality (Chisholm and Saxena 2012BIB-3_1, Chisholm et al 12 
2012BIB-3_1, Ginsberg et al 2012BIB-3_1, Ortegón, Lim, Chisholm and 13 
Mendis 2012BIB-3_1, Ortegon et al 2012BIB-3_1, Baltussen and Smith 14 
2012BIB-3_1). This is interesting for a number of reasons: the analysis 15 
extends beyond the disease areas of the challenge paper and the ‘best 16 
buy’ analysis, including road traffic injuries, mental health, and sensory 17 
                                                                                                                        
health information and warning, bans on advertising, promotion and 
sponsorship. Other possibilities to reduce CVD and cancer risks not 
presented include; screening in primary care for CVD risk, counselling 
and multi-drug therapy for individuals with >30 CVD risk, prevention 
of cervical cancer through screening and lesion removal. 
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loss disorders; it provides a more accountable and direct comparison of a 1 
broader range of interventions; and, for the interventions that are not 2 
dominated9 (within disease clusters), a probabilistic cost-effectiveness 3 
analysis indicates some degree of the uncertainty. However, there are still 4 
limitations with using this analysis as a full critique or validation of 5 
investment options presented in the challenge paper. For example, the 6 
analysis is restricted to two WHO regions, one intervention proposed by 7 
Jha et al is excluded entirely (hepatitis B vaccination10), and the drug 8 
based interventions proposed in the challenge paper are potentially 9 
grouped slightly differently11. 10 
Insert table 3.1.2 here 11 
The second exercise, led by Chisholm, provides strong support for 12 
increasing tobacco tax as it is a particularly cost-effective intervention for 13 
both WHO regions (see Table 2). However, salt reduction and all salt 14 
                                                 
9 An intervention is ‘dominated’ if it is more costly and/or less effective 
than other (more efficient) interventions 
10 Because treatment of liver disease was considered not to have strong 
evidence of effectiveness and aspects of prevention of hepatitis B and 
cirrhosis were ‘covered’ already in some of the alcohol interventions 
evaluated (Ginsberg et al 2012BIB-3_1). 
11 This isn’t entirely clear as the WHO based analysis does allow 
combinations of therapies. 
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based interventions were dominated by other options (within their 1 
disease/risk factor cluster), as was treatment of AMI with aspirin, ace 2 
inhibitor and beta blockers and all of the, drug therapy based, 3 
secondary/tertiary prevention of myocardial infarction. This indicates that 4 
other interventions could achieve greater DALY gain per $ spent. 5 
Insert table 3.1.3 here 6 
Chisholm et al (2012)BIB-3_1 note that, compared with all other 7 
interventions for controlling chronic disease, “antibiotic treatment of 8 
chronic otitis media (a persistent inflammation of the middle ear) is the 9 
most cost-effective intervention in the two regions (<$Int100/DALY 10 
saved), while extraction of cataracts and proactive screening for hearing 11 
loss are among the biggest contributors to population health gain”. The 12 
detailed results are provided in Table 3 and it can be seen that, even in 13 
comparison with tax increases for tobacco, these interventions are more 14 
cost-effective. However, with a population of 2 million needing cataract 15 
surgey in Africa and 4.2 million in South East Asia (Baltussen and 16 
Smith), the annual treatment is unlikely make a significant dent in the 17 
hypothetical budget facing the Copenhagen Consensus Panel given that 18 
the number of interventions selected are restricted to five. However, this 19 
is unlikely to be the case for an intervention such as treatment based on 20 
absolute risk of a cardiovascular event in next 10 years with statin, 21 
diuretic, β blocker, and aspirin for cardiovascular risk of 5% (CVD-11). 22 
Page 583 of 2253 
In this case, the annual DALYs saved per million population is 3,163 at a 1 
cost of Int$ 0.33 per capita and both an average and incremental cost-2 
effectiveness ratio of Int$104 per DALY averted. 3 
Conclusion 4 
Whether an additional investment of upto $75 billion should comprise the 5 
five interventions proposed by Jha and colleagues is questionable. The 6 
initial filtering through calculations of disease burden combined with a 7 
lack accounting for uncertainty and a sensitivity analysis that did not 8 
question the relative rankings of interventions suggests that the best buys 9 
are unlikely to be presented. Other evidence suggests that alternative 10 
interventions could indeed provide a better return on investment. 11 
Examples include cataract surgery, antibiotic treatment for otitis media 12 
and primary prevention of CVD. However, the cost-effectiveness analysis 13 
on which the latter suggestions are made do not account for the level of 14 
health system support needed. Jha et al do discuss this at length and it 15 
would have been interesting to see both a quantification of health system 16 
support needed for the proposed interventions in the challenge paper as 17 
well as understanding why this would not support the range of alternative 18 
interventions highlighted in the recent series of papers in the British 19 
Medical Journal. 20 
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Table 3.1.1 Replication and extension of Jha et al estimate for hepatitis B 1 
vaccination 2 
 3 
  Jha et al 
estimates 
Less 
favourable 
assumptions 
More 
favourable 
assumptions 
Birth cohort 136,000,000 136,000,000 136,000,000 
Average cost vaccination 3.6 4.6 2.7 
Annual cost of vaccinating all 
children 489,600,000 625,600,000 367,200,000 
Proportion vaccinated 0.75 0.64 0.75 
New proportion to be vaccinated 1 1 1 
1% linear cost 4,896,000 6,256,000 3,672,000 
Extra% coverage re expected cost 122,400,000 225,216,000 91,800,000 
Deaths from Hep B 600,000 1,400,000 600,000 
Deaths assumed potentially savable 
from HBV given current and future 
vaccination coverage  150,000 176,400 150,000 
DALYs lost per death 20 20 20 
DALYs 3,000,000 3,528,000 3,000,000 
Value of death/DALY averted 1,000 1,000 1,000 
Value of death averted 150,000,000 176,400,000 150,000,000 
TT 
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Value of DALY averted 3,000,000,000 3,528,000,000 3,000,000,000 
Undiscounted B:C ratio (death) 1 1 2 
Undiscounted B:C ratio (DALYs) 25 16 33 
discounted deaths (3%, 40yrs) 45,179 39,360 60,985 
discounted DALYs 903,583 787,203 1,219,709 
Discounted value deaths 45,179,132 39,360,160 60,985,449 
Discounted value DALYs 903,582,636 787,203,205 1,219,708,979 
Discounted benefit-cost ratio deaths 0 0 1 
Discounted benefit-cost ratio DALYs 7 3 13 
 1 
2 
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Table 3.1.2 Costs and effects of a 50% increase in tobacco tax (from 40–60%) 1 
 2 
  WHO Africa Region WHO South East Asia Region 
Annual DALYs saved per million 
population 687 3,043 
Annual cost per capita (Int $) 0.31 0.27 
Average cost-effectiveness ratio 
(Int $) 448 87 
Incremental cost-effectiveness ratio 
(Int $)  448 87 
Sensitivity horizontal ellipse stretching 
from roughly Int$ 0.1–0.7 per 
capita and 200–1,200 DALYS 
averted per year per million 
population (i.e. most uncertainty 
with effectiveness) 
horizontal ellipse stretching from 
roughly Int$ 0.1–0.9 per capita 
and 1,200–5,500 DALYS averted 
per year per million population 
(i.e. most uncertainty with 
effectiveness) 
 3 
Source: Ortega et al (2012)BIB-3_1 4 
5 
TT 
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Table 3.1.3 Costs and effects of two alternative interventions for investment 1 
 2 
 WHO Africa Region WHO South East Asia Region 
Costs and effects of achieving 95% coverage of cataract, extracapsular cataract extraction with 
posterior chamber lens implant (CAT-6) 
Annual DALYs saved per million 
population 6,281 6,447 
Annual cost per capita (Int $) 0.73 0.63 
Average cost-effectiveness ratio 
(Int $) 116 97 
Incremental cost-effectiveness ratio 
(Int $)  117 97 
Sensitivity Not possible to read from graph 
Horizontal ellipse from (roughly 
1,800–10,800 DALYs and Int$ 
0.1–1.0 per capita 
Treatment based on absolute risk of a cardiovascular event in next 10 years with statin, diuretic, β 
blocker, and aspirin for cardiovascular risk of 5% (CVD-11) 
Annual DALYs saved per million 
population 3163 2984 
Annual cost per capita (Int $) 0.33 0.41 
Average cost-effectiveness ratio 
(Int $) 104 138 
Incremental cost-effectiveness ratio 104 146 
TT 
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(Int $)  
Sensitivity 
Horizontal ellipse from 
(roughly)800–5,200 DALYs 
lost per million population and 
(roughly) $0.2 to 0.5 per capita 
Horizontal ellipse from 
(roughly)1,000–5000 DALYs lost 
per million population and 
(roughly) $0.2 to 0.5 per capita 
Sources: Baltussen and Smith (2012)BIB-3_1, Ortegon et al (2012)BIB-3_1 1 
2 
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Figure Caption 1 
Figure 3.1.1 Variability in point estimates of incremental cost-effectiveness following 2 
sensitivity analysis 3 
Source: Briggs (1995) 4 
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